NasdaqGS - Delayed Quote USD

Erasca, Inc. (ERAS)

1.8900 +0.0100 (+0.53%)
At close: April 26 at 4:00 PM EDT
1.9500 +0.06 (+3.17%)
After hours: April 26 at 7:37 PM EDT

Key Executives

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Jonathan E. Lim M.D. Co-Founder, Chairman & CEO 940.32k -- 1972
Dr. David M. Chacko M.D. CFO & Chief Business Officer 616.76k -- 1984
Dr. Michael D. Varney Ph.D. Chairman of Research & Development, Scientific Advisory Board Member and Director 83.26k -- 1958
Dr. Nik Chetwyn Ph.D. Chief Operating Officer -- -- --
Mr. Ebun S. Garner Esq., J.D. General Counsel & Corporate Secretary 510.98k -- 1972
Dr. Lisa Tesvich-Bonora Ph.D. Chief People Officer -- -- --
Mr. Brian L. Baker CPA, M.S. Senior Vice President of Finance -- -- 1967
Ms. Chandra D. Lovejoy M.S. Chief Regulatory Affairs Officer -- -- 1971
Dr. Robert Shoemaker Ph.D. Senior Vice President of Research -- -- 1981
Dr. Shannon R. Morris M.D., Ph.D. Chief Medical Officer -- -- 1970

Erasca, Inc.

3115 Merryfield Row
Suite 300
San Diego, CA 92121
United States
858 465 6511 https://www.erasca.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
126

Description

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Corporate Governance

Erasca, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 8. The pillar scores are Audit: 6; Board: 7; Shareholder Rights: 8; Compensation: 8.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

Related Tickers

ORIC ORIC Pharmaceuticals, Inc.
8.07
+5.22%
 
GLUE Monte Rosa Therapeutics, Inc.
5.33
-2.20%
 
ZNTL Zentalis Pharmaceuticals, Inc.
11.06
+0.68%
 
BOLD Boundless Bio, Inc.
11.64
-3.56%
 
YMAB Y-mAbs Therapeutics, Inc.
14.71
-0.88%
 
RVMD Revolution Medicines, Inc.
35.96
+1.78%
 
ENVB Enveric Biosciences, Inc.
0.8950
-2.45%
 
ELYM Eliem Therapeutics, Inc.
3.9800
+17.40%
 
FULC Fulcrum Therapeutics, Inc.
7.14
+0.14%
 
LYEL Lyell Immunopharma, Inc.
2.1700
-1.36%